Brazil to produce atazanavir to supply SUS demand; strong pharma growth forecast for 2014
Following the Official Gazette market application filling for the drug atazanavir sulfate, an HIV protease inhibitor, on January 13, the Institute of Pharmaceutical Technology (Farmaguinhos/Fiocruz will be responsible for production of the drug concentrations in 150mg , 200mg and 300mg.
As a result, Brazil will have the assurance of supply of the drug to attend the Unified Health System (SUS) demand, reports Juliane Carvalho on Brazil Pharma News.
The domestic production of the antiretroviral is the result of a Productive Development Partnership ( PDP ) signed between the Ministry of Health - through Farmaguinhos – and US Pharma major Bristol-Myers Squibb (NYSE: BMY, the developer of the drug. The agreement includes the transfer of technology, manufacturing and distribution of the drug for five years. In the first two years of the partnership, the US firm is committed to providing the medicine to Farmaguinhos, which has been going on since last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze